Pharmacogenomics and personalized medicine in neuropsychiatry.
paper
Cited
Public
- Authors
- McMahon, Francis J; Insel, Thomas R
- Year
- 2012
- Journal
- Neuron
- PMID
- 22681682
- DOI
- 10.1016/j.neuron.2012.05.004
- PMCID
- PMC3407812
Despite the need for more effective treatments for psychiatric disorders, development of new medications has stalled. Here we discuss the promise of personalized medicine in developing more efficacious and individualized pharmacotherapies that take into account genetic variation and target groups of patients who share biology, not just symptoms.
The nested relationship between personalized medicine, genomic medicine, and pharmacogenetics and genomics.
Approaches to the pharmacogenomics of psychotropic medications. Individual variation reflects both genetic and non-genetic factors that converge on the absorption, distribution, central target, metabolism, and toxicity of medications.
1–20 of 23
Next →
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | 2015 | 26142345 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Differential <i>SP4</i> expression and HSP60 abundance in buccal swabs from patients with schizophrenia. | Crosta CM et al. | — | 2026 | → |
| Functional implications of polygenic risk for schizophrenia in human neurons. | Michael Deans PJ et al. | — | 2026 | → |
| Fifty years of executive control research in attention-deficit/hyperactivity disorder:What we have learned and still need to know. | Schachar RJ | — | 2023 | → |
| A life course view on depression: Social determinants of depressive symptom trajectories over 25 Years of Americans' Changing Lives. | Sinkewicz M et al. | — | 2022 | → |
| Convergent and non-additive impact of schizophrenia risk genes in human neurons | Deans PM et al. | — | 2022 | — |
| "It's what makes us unique": Indigenous Australian perspectives on genetics research to improve comorbid mental and chronic disease outcomes. | Nasir BF et al. | — | 2022 | → |
| Putting Genetics to Work in the Psychiatric Clinic. | McMahon FJ | — | 2022 | → |
| Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders. | Levchenko A et al. | — | 2020 | → |
| Differences among Research Domain Criteria score trajectories by Diagnostic and Statistical Manual categorical diagnosis during inpatient hospitalization. | McCoy TH et al. | — | 2020 | → |
| Predicting individual clinical trajectories of depression with generative embedding. | Frässle S et al. | — | 2020 | → |
| Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream. | Di W et al. | — | 2020 | → |
| New considerations for hiPSC-based models of neuropsychiatric disorders. | Hoffman GE et al. | — | 2019 | → |
| Personalized and precision medicine as informants for treatment management of bipolar disorder. | Perugi G et al. | — | 2019 | → |
| Synergistic effects of common schizophrenia risk variants. | Schrode N et al. | — | 2019 | → |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | — | 2018 | → |
| The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine. | Pisanu C et al. | — | 2018 | → |
| A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. | Kim YK et al. | — | 2017 | → |
| Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome. | Green IW et al. | — | 2016 | → |
| Effectiveness of traditional healers in treating mental disorders: a systematic review. | Nortje G et al. | — | 2016 | → |
| An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine. | Schmauss C | — | 2015 | → |
| Can adaptive treatment improve outcomes in family-based therapy for adolescents with anorexia nervosa? Feasibility and treatment effects of a multi-site treatment study. | Lock J et al. | — | 2015 | → |
| Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial. | Carroll KM et al. | — | 2015 | → |
| Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach. | Chen FS et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. | Young JW et al. | — | 2015 | → |
| Targeting dynamic interplay among disordered domains or endophenotypes to understand complex neuropsychiatric disorders: Translational lessons from preclinical models. | Kalueff AV et al. | — | 2015 | → |
| The current and potential impact of genetics and genomics on neuropsychopharmacology. | Harrison PJ | — | 2015 | → |
| The epigenome, 4D nucleome and next-generation neuropsychiatric pharmacogenomics. | Higgins GA et al. | — | 2015 | → |
| The promise of psychiatric pharmacogenomics. | Hamilton SP | — | 2015 | → |
| Carving bipolarity using a lithium sword. | Malhi GS et al. | — | 2014 | → |
| Epigenetic and pharmacological regulation of 5HT3 receptors controls compulsive ethanol seeking in mice. | Barker JM et al. | — | 2014 | → |
| Longitudinal monitoring of the serotonin transporter gene expression to assess major depressive episode evolution. | Belzeaux R et al. | — | 2014 | → |
| Moving psychopharmacological drug development to the developing world. | Sathyanarayana Rao TS et al. | — | 2014 | → |
| Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. | McIntyre RS et al. | — | 2014 | → |
| Prediction of treatment outcomes in psychiatry--where do we stand ? | McMahon FJ | — | 2014 | → |
| Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention. | Hsu WC et al. | — | 2014 | → |
| The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. | Hadley D et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Lee CS et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Birnbaum R et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Vlachadis N et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Ikeda M et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Consortium on Lithium Genetics et al. | — | 2014 | → |
| Variant GADL1 and response to lithium in bipolar I disorder. | Anghelescu I et al. | — | 2014 | → |
| Behavior genetics: past, present, future. | Jaffee SR et al. | — | 2013 | → |
| Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells. | Ess KC | — | 2013 | → |
| Personalized medicine in Alzheimer's disease and depression. | Souslova T et al. | — | 2013 | → |
| Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. | Maccarrone G et al. | — | 2013 | → |
| Update on the treatment of anorexia nervosa: review of clinical trials, practice guidelines and emerging interventions. | Watson HJ et al. | — | 2013 | → |
| What is the role of pharmacogenetics in clinical psychiatry? | Lombard J et al. | — | 2013 | → |
| Opportunities for bioinformatics in the classification of behavior and psychiatric disorders. | Chesler EJ et al. | — | 2012 | → |